"There are however pharmaceutical companies actively involved in researching and developing new antimicrobial medicines. One successful initiative – the Innovative Medicines Initiative (IMI) – has brought together several pharmaceutical companies and the public sector to invest €223,7 million in developing a programme to tackle antimicrobial resistance. But more still needs to be done and we believe that for there to be a continual supply of effective antibiotics, a comprehensive review of the R&D environment and good stewardship are required urgently.
“Last year the ABPI set up an industry taskforce to look at this problem. Twelve years after the publication of the 2000 UK AMR Strategy, we were pleased to see that Department of Health announced its intention to review their approach to dealing with antimicrobial resistance. We responded to the draft strategy with our recommendations and look forward to its publication so this serious problem can be addressed.”
ABPI Press Office
Tel: +44 (0) 20 7747 1410
Mobile: +44 (0) 7850 312064
Notes to editors
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by Government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.